Options Update: Human Genome November volatility at 248 into data
Human Genome closed at $19.97. HGSI's Benlysta, a lupus treatment, is expected to have phase 3 data released on November 2. HGSI November option implied volatility is at 249, December is at 170, January is at 143 and April is at 112, according to Track Data, suggesting large movement.
Join the discussion below, or Read more at Blogging Stocks.
#1 Nov 1, 2009
Research on new Benlysta lupus drug has been completed: http://www.orderonlinedrugs.com/drug-news/200...
Add your comments below
|Transcept's Intermezzo Has Significant Long Ter... (Jan '12)||Oct '13||Jessamyn||8|
|US adviser on board of firm that sold anthrax drug (May '13)||May '13||KittenKoder||1|
|GSK secures $3.6bn HGS deal (Jan '13)||Jan '13||kmc2749||1|
|Human Genome agrees to GlaxoSmithKline takeover (Jul '12)||Jul '12||HumanSpirit||1|
|human genome (May '09)||Jun '12||Species||2|
|Human Genome rejects GlaxoSmithKline's $2.6B bid (Apr '12)||Apr '12||Duh Moment||3|
|Shares of Human Genome Sciences ([[HGSI]] -7.1%... (Mar '12)||Mar '12||aliya||2|
Find what you want!
Search Human Genome Sciences Forum Now
Copyright © 2016 Topix LLC